| http://www.w3.org/ns/prov#value | - The Second is U.S. Patent No. 5,540,938 (???the ???938 patent???), the claims of which relate to methods for treating a neurological disease, such as MS, and cover the use of a sustained release dalfampridine formulation, such as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg for improving walking in people with MS. In October 2012, the USPTO determined that the ???938 patent is entitled t
|
